Camp4 Therapeutics Corporation
CAMP
$4.36
$0.163.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.29M | 348.00K | 795.00K | 1.50M | 858.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.29M | 348.00K | 795.00K | 1.50M | 858.00K |
| Cost of Revenue | 10.16M | 8.36M | 9.36M | 10.34M | 10.15M |
| Gross Profit | -8.87M | -8.01M | -8.56M | -8.85M | -9.29M |
| SG&A Expenses | 4.21M | 4.77M | 4.60M | 4.18M | 3.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.37M | 13.12M | 13.95M | 14.53M | 13.96M |
| Operating Income | -13.07M | -12.78M | -13.16M | -13.03M | -13.10M |
| Income Before Tax | -18.33M | -40.28M | -15.10M | -12.59M | -12.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.33M | -40.28M | -15.10M | -12.59M | -12.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.33M | -40.28M | -15.10M | -12.59M | -12.43M |
| EBIT | -13.07M | -12.78M | -13.16M | -13.03M | -13.10M |
| EBITDA | -12.55M | -12.40M | -12.74M | -12.60M | -12.68M |
| EPS Basic | -0.32 | -0.75 | -0.55 | -0.62 | -0.62 |
| Normalized Basic EPS | -0.20 | -0.47 | -0.33 | -0.39 | -0.39 |
| EPS Diluted | -0.32 | -0.75 | -0.55 | -0.62 | -0.62 |
| Normalized Diluted EPS | -0.20 | -0.47 | -0.33 | -0.39 | -0.39 |
| Average Basic Shares Outstanding | 57.92M | 53.86M | 27.27M | 20.16M | 20.15M |
| Average Diluted Shares Outstanding | 57.92M | 53.86M | 27.27M | 20.16M | 20.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |